StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report issued on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Price Performance
Shares of Galmed Pharmaceuticals stock opened at $0.30 on Monday. The business has a 50 day simple moving average of $0.33 and a two-hundred day simple moving average of $0.36. Galmed Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $1.12. The stock has a market capitalization of $1.54 million, a P/E ratio of -0.13 and a beta of 0.69.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last announced its earnings results on Thursday, May 30th. The biopharmaceutical company reported ($0.23) EPS for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Stories
- Five stocks we like better than Galmed Pharmaceuticals
- What is the S&P 500 and How It is Distinct from Other Indexes
- First Solar Stock: The Dawn of a New Rally in Share Prices
- 3 Small Caps With Big Return Potential
- Mastercard Stock’s Q2 Financial Results Outshine Competitors
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Tobacco Giant’s Shares Fall on EPS Miss, Lackluster Pouch Gains
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
